蚓激酶治疗缺血性脑卒中的研究进展

Progress of Lumbrokinase for the treatment of ischemic stroke

蚓激酶(LK)是一组纯化于蚯蚓的蛋白水解酶,具有纤维蛋白溶酶原激活物及纤维蛋白溶酶活性,可直接或间接降解纤维蛋白,并通过降纤和降低血液黏度发挥血栓溶解和防止血栓形成的药理活性。目前,临床上应用LK治疗血栓性疾病,集中于缺血性脑卒中。联合常规治疗手段,LK可改善急性缺血性脑卒中患者的血液流变学,降低纤维蛋白原含量,提高神经功能评分和生活质量,疗效好且安全;另外,LK联合阿司匹林可降低缺血性脑卒中的复发率。因此,LK在治疗和预防缺血性脑卒中具有一定的潜能。本文对LK的药理活性及临床治疗缺血性脑卒中的文献进行综述,以期为LK的进一步的开发利用提供理论支撑。

Lumbrokinase(LK)is purifed from earthworm and pertained serine protein.It could directly and indirectly degrade fibrin to promote thrombolysis and prevent formation of thrombus by defibrating and lowering blood viscosity due to pharmacological activity of plasminogen activator and plasmin.At present,LK used in thrombotic diseases is proved effective and safe,especially ischemic stroke.Combined with basic treatment,LK can improve hemorheology in patients with acute ischemic stroke,reduce fibrinogen content,improve neurological function score and quality of life,and it has a good and safe curative effect.Besides,LK could decrease recurrence rate of ischemic stroke with Aspirin.Therefore,LK has certain potential in the treatment and prevention of ischemic stroke.To provide theoretical support for further development and utilization of LK,this paper summarizes pharmacological activity and clinical application of ischemic stroke.